RCUS (Arcus Biosciences) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 09, 2026)


RCUS Arcus Biosciences Inc RCUS
46 GF Score
Price $30.04
GF Value $13.19
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arcus Biosciences 5-Year Yield-on-Cost %?

Arcus Biosciences RCUS -0.73% 46 5-Year Yield-on-Cost % is 0.00 as of Jul. 09, 2026. GuruFocus rates RCUS with a GF Score™ of 46/100 and a GF Value™ of $13.19 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 153 Biotechnology companies, Arcus Biosciences ranks worse than 653594.12% on this metric.

Arcus Biosciences's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Arcus Biosciences's 5-Year Yield-on-Cost % or its related term are showing as below:



RCUS's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.66
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Arcus Biosciences  (NYSE:RCUS) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Arcus Biosciences 5-Year Yield-on-Cost % Related Terms


RCUS vs NAMS, CRNX, CPRX: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Arcus Biosciences's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcus Biosciences 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcus Biosciences's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Arcus Biosciences's 5-Year Yield-on-Cost % falls into.


RCUS
46GF Score
Arcus Biosciences Inc RCUS
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcus Biosciences 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Arcus Biosciences is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Arcus Biosciences (RCUS) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 09, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Arcus Biosciences and its competitors. According to the industry distribution chart, Arcus Biosciences ranks #999999 out of 153 companies in the Biotechnology industry.
Is Arcus Biosciences' 5-Year Yield-on-Cost % too high?
Arcus Biosciences' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Arcus Biosciences ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arcus Biosciences has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcus Biosciences' 5-Year Yield-on-Cost % compare to NAMS and CRNX?
According to the Biotechnology industry distribution chart, Arcus Biosciences ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places Arcus Biosciences in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.66, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Arcus Biosciences and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcus Biosciences's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcus Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Arcus Biosciences (RCUS) is currently considered Significantly Overvalued. The stock's GF Value™ is $13.19, compared to a current price of $30.04 — trading 127.7% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Arcus Biosciences' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Arcus Biosciences (RCUS), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcus Biosciences (RCUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arcus Biosciences stock appears to be overvalued. The current stock price of $30.04 is trading 127.7% above its estimated GF Value™ of $13.19. GuruFocus considers Arcus Biosciences to be Significantly Overvalued.

Key valuation signals for RCUS:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: $13.19 vs. price of $30.04 (127.7% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the RCUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arcus Biosciences Business Description

Address 3928 Point Eden Way, Hayward, CA, USA, 94545
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
46GF Score

Get the complete analysis for RCUS

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$30.04
Price
$13.19
GF Value